Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TJ011133 plus azacitidine vs azacitidine in higher-risk MDS
CTR20230090Phase 3Terminated
- Sponsor
- I-Mab
- Start
- Jan 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lemzoparlimab in myelodysplastic syndrome (MDS), sponsored by I-Mab. Started Jan 2023; status: terminated.
02
Drugs
lemzoparlimab
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on CTR20230090.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230090.